Literature DB >> 15945499

Significant decrease of IgE antibodies after a three-year controlled study of specific immunotherapy to pollen allergens in children with allergic asthma.

A Cantani1, M Micera.   

Abstract

BACKGROUND: Specific immunotherapy (SIT) in children being not an optional treatment should be administered as soon as possible, also in children aged 2-3 years, due to the very early asthma and rhinitis onset, contrarily to opponents continuing to stress the danger of anaphylactic reactions without displaying reliable data.
MATERIALS AND METHODS: We report 56 children who underwent SIT and 56 controls seen consecutevely at the Allergy and Immunology Division, Department of Pediatrics, University of Rome "La Sapienza". The control group was treated with all appropriate medications.
RESULTS: They were highly in favor of SIT with statistically significant differences. We stress that IgE antibodies significantly decreased after treatment only in the study group, and IgG antibodies very significantly increased after treatment only in the study group. DISCUSSION: We demonstrate that SIT is the only treatment which can alter the natural course of respiratory diseases, whereas drugs represent only a symptomatic treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15945499

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  4 in total

Review 1.  Subcutaneous and sublingual immunotherapy in children: complete update on controversies, dosing, and efficacy.

Authors:  Désirée Larenas-Linnemann
Journal:  Curr Allergy Asthma Rep       Date:  2008-11       Impact factor: 4.806

2.  A possible link between sinusitis and lower airway hypersensitivity: the role of Staphylococcal enterotoxin B.

Authors:  Tao Liu; Bin-Quan Wang; Ping-Chang Yang
Journal:  Clin Mol Allergy       Date:  2006-05-07

3.  Reduction of Allergic Lung Disease by Mucosal Application of Toxoplasma gondii-Derived Molecules: Possible Role of Carbohydrates.

Authors:  Elke Korb; Mirjana Drinić; Angelika Wagner; Nora Geissler; Aleksandra Inic-Kanada; Roman Peschke; Anja Joachim; Ursula Wiedermann; Irma Schabussova
Journal:  Front Immunol       Date:  2021-03-10       Impact factor: 7.561

4.  Specific immunotherapy with mugwort pollen allergoid reduce bradykinin release into the nasal fluid.

Authors:  Radoslaw Gawlik; Alicja Grzanka; Barbara Jawor; Eugeniusz Czecior
Journal:  Postepy Dermatol Alergol       Date:  2016-08-16       Impact factor: 1.837

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.